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OBJECTIVES Characterize the incidence, clinical and etiologic features and outcomes of advanced
congestive heart failure.
BACKGROUND This condition is frequent, severe and costly, yet no population-based epidemiological data
are available that take into account modern advances in diagnosis and therapy.
METHODS The EPICAL (EPide´miologie de l’Insuffisance Cardiaque Avance´e en Lorraine) study was
based on a comprehensive registration of patients with ACHF (defined as hospital admission
for presence of NYHA class III or IV symptoms, radiological and/or clinical signs of
pulmonary congestion and/or signs of peripheral edema, left ventricular ejection fraction
,30% or a cardiothoracic ratio .60%) in patients aged 20–80 years during year 1994, in the
community of the Lorraine region in France (n 5 1,592,263). Average follow-up for
readmission to hospital and mortality was 18 months (12–24 months).
RESULTS From 2,576 registered patients, 499 were enrolled into the study among which, 358 were new
presentations. This represents a crude incidence rate of 225 per million. 46.3% had a coronary
heart disease. One-year mortality rate was 35.4% and the rate of mortality and/or readmission
to hospital was 81%. Patients were admitted to hospital 2.05 times per year (64% of these for
worsening heart failure), spending 27.6 days per year in hospital. Twenty received a heart
transplant (4%). On discharge, 74.8% were using ACE inhibitors and 49.6% digitalis.
CONCLUSIONS Mortality and hospitalization rate of advanced CHF remain very high despite recent
therapeutic progress. Major therapeutic and managed-care research is required. (J Am Coll
Cardiol 1999;33:734–42) © 1999 by the American College of Cardiology
With the increasing mean age of the population and the
longer survival of patients with chronic heart disease
(CHD), the growing prevalence of congestive heart failure
(CHF) has been interpreted as an “ironic failure of success”
(1). Indeed, as medical and surgical advances have length-
ened survival rates in CHD patients, the number who live
long enough to develop CHF has increased. Consequently,
as a common sequel of many forms of cardiovascular disease,
CHF is becoming a major health problem.
Once overtly manifest, CHF is an extremely lethal
condition associated with a very poor quality of life and
prognosis. Advanced CHF is associated with a shorter life
expectancy than many common malignancies (2), and its
present prognosis has remained unchanged since the Fra-
mingham survey (1948–1988) (3). Recent improvements in
the medical and surgical management of patients with
advanced CHF include the use of vasodilators, angiotensin-
converting enzyme (ACE) inhibitors, viable myocardium
revascularization, heart transplantation and cardiac assist
device systems. These management strategies are, however,
not used sufficiently or properly by the medical community
(4,5).
Earlier epidemiological descriptions of CHF (6,7) were
based on small surveys, limited data, hospital records or
death certificates. No recent, nationally representative epi-
demiological survey has been published taking these recent
improvements in the medical and surgical management of
patients with CHF into account, and to date, only single-
center, hospital-based studies of patients referred for (8),
awaiting cardiac transplantation for (9) or presenting to the
emergency room for decompensated CHF (10) are available
for reference.
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The EPICAL study (EPide´miologie de l’Insuffisance
Cardiaque Avance´e en Lorraine), a prospective observa-
tional, community-based, epidemiological evaluation of ad-
vanced CHF, was therefore undertaken to investigate the
incidence, quality of life, prognosis and use of healthcare
resources related to CHF in a local large French commu-
nity. The aim of the study was to focus on patients
hospitalized with advanced CHF, defined by the presence of
signs and symptoms and poor systolic function.
METHODS
Study population. Lorraine is an urban and rural area
situated in the Northeast of France. Following an intensive
briefing concerning the rationale of the study, physicians
(mainly cardiologists and also internists, pneumologists,
emergency and intensive care and rehabilitation specialists)
representing all primary care and referral centers into all the
private and public hospitals providing healthcare to the
Lorraine community agreed to participate in the study.
There are 35 participating hospitals (list at Appendix 2)
among which three were university hospitals including one
transplant center, 26 were community hospitals and six were
private hospitals.
Inclusion criteria and enrollment. On admittance to hos-
pital, patients presenting with a history and/or symptoms
compatible with the diagnosis of advanced CHF were
screened and registered prospectively by the attending
investigator-physician and subsequently investigated by
trained research nurses using a structured questionnaire.
Registration was also active and randomly and indepen-
dently audited by trained research nurses. All cases were
validated via a thorough review of the medical records by a
steering committee composed of five senior cardiologists:
one cardiac surgeon, one clinical pharmacologist, one phys-
iologist and two epidemiologists.
Inclusion criteria for enrollment into the study included:
established residence in the Lorraine region, age between 20
and 80 years (inclusive), admission to hospital during 1994,
diagnosis of advanced CHF (defined as at least one hospital
admission during a one-year period with NYHA class III or
IV symptoms of CHF, radiological and clinical signs of
pulmonary congestion, and/or signs of peripheral edema,
left ventricular ejection fraction [LVEF] ,30% [determined
by the technique routinely available in the hospital con-
cerned, mainly echocardiography] or a cardiothoracic ratio
[CTR] .60%).
Data collection and follow-up. After enrollment, a case
record form for every patient was collected by the research
nurse using the medical records of each patient, as well as
interviews with the attending physician, the patient and/or
the patient’s relatives. Data on risk factors, comorbidities,
history of cardiac disease and of CHF, as well as data
regarding hospitalizations for CHF during the previous 18
months, were recorded. During the hospitalization imme-
diately preceding enrollment, the results of clinical and
laboratory tests (Table 1 and 2) with potential prognostic
value were also collected. After obtaining informed consent,
every surviving enrolled patient was visited at home by a
trained research nurse one month after discharge and
subsequently every four months. Data concerning survival
status, heart transplantation, subsequent hospital readmis-
sions, length of hospital stay and drug prescriptions were
collected using structured questionnaires.
Etiology of CHF. Ischemic heart disease was defined by
the presence of at least one of the following: history of acute
myocardial infarction (MI; with at least two of the following
signs: typical chest pain lasting more than 20 min, Q-wave
MI on EKG, significant cardiac enzyme elevation), typical
angina with ischemic signs on resting EKG and/or exercise
EKG and/or thallium scan, significant coronary artery
narrowing on coronary angiogram, history of coronary
angioplasty or coronary artery bypass graft (CABG). Val-
vular and congenital heart disease were defined by the
presence or a history of hemodynamically significant valvu-
lar or congenital disease, respectively. Patients with dilated
cardiomyopathy with no criteria for ischaemic, valvular or
congenital heart disease were separated into two subgroups
according to the presence or the absence of one or several of
the following contributing factors: history of hypertension,
present alcohol abuse and presence of other rare causes of
specific cardiomyopathy (11).
Data analysis. Incidence rates were calculated from the
observed number of new cases of CHF divided by the age-
and sex-specific person-years of observation. An estimation
of the number of people in the Lorraine region aged
between 20 and 80 years was derived from 1990 census data
(95% confidence intervals [CI] were constructed around the
point estimates of incidence by assuming a Poisson distri-
bution). Subgroup comparisons were made with the Pearson
Chi-square test for each variable, expressed as a percentage
of all patients. Nonnormally distributed variables were
analyzed using the nonparametric Mann-Whitney U test.
Survival and hospitalization function estimates as well as
event rates at one year were derived using the method of
Kaplan and Meier (12). The date of entry was the first day
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
CABG 5 coronary artery bypass graft
CHD 5 coronary heart disease
CHF 5 congestive heart failure
CI 5 confidence interval
CTR 5 cardiothoracic ratio
EPICAL 5 EPide´miologie de l’Insuffisance Cardiaque
Avance´e en Lorraine
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
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of admission to hospital immediately preceding enrollment
into the study; the endpoint date was 31 December 1995.
The relative risk conferred by advanced CHF was calculated
according to gender and age as the ratio between the rate of
death within the EPICAL cohort and the rate of death
from all causes within the general population of Lorraine
during 1994. The analyses used to estimate survival were
also used to estimate hospital readmission-free survival.
After the examination of hospital records by an appropriate
events committee, hospital readmissions were classified as
being related to worsening CHF, other cardiac causes or
noncardiac causes.
Computations were performed using BMDP software
(13). A two-sided probability value of 0.05 or less was
required for statistical significance. Numerical values are
expressed as mean 6 95% CI.
RESULTS
Registration of prospective patients began in September
1993 and ended in mid-June 1995. After an initial phase
required for stabilization of the weekly average rates of
registrations and of enrollments, the registration rate
reached a plateau between January 1994 and early 1995 and
was further ascertained by “capture-recapture analysis.” On
this basis, it was decided to enroll all eligible patients
registered between 1 January 1994 and 31 December 1994.
A total number of 2,576 registrations were made during this
period, corresponding to 2,033 patients (543 registrations
were duplicates). Of the 2,033 registered patients 1,534
were excluded (54 not from the Lorraine Region, 552 not
Table 1. Demographic and Clinical Characteristics and History of Cardiac Disease of the Patients
All Cases
(n 5 499) CHD (n 5 231)
Non-CHD
(n 5 268) p*
Sex ratio (M/F) 3.2 4.5 2.5 0.0058
Age (years) 64.6 [63.7–65.5] 66.1 [64.9–67.4] 63.3 [62.0–64.7] 0.0025
Cigarette use (%) 57.3 64.5 51.1 0.0026
History of diabetes (I1II) (%) 25.6 32.5 19.8 0.0012
History of hypertension (%) 43.7 44.6 42.9 0.7063
Alcohol abuse (%) 18.8 10.8 25.7 , 0.0001
History of hyperlipidaemia (%) 27.0 36.8 18.7 , 0.0001
First diagnosis of cardiac disease (%) 0.0541
,3 months 19.1 14.3 23.4
3–12 months 6.6 8.3 4.9
1–5 years 28.1 27.0 28.7
5–10 years 19.5 22.2 17.4
.10 years 26.7 28.3 25.7
History of CABG (%) 9.2 19.9 0
History of coronary angioplasty (%) 6.0 13.0 0
History of valve surgery (%) 6.0 2.6 9.0 0.0029
Pacemaker (%) 9.6 10.0 9.3 0.8124
Implantable defibrillator (%) 0.6 0.9 0.4 0.5985
Quetelet index (kg/m2) 25.5 [25.1–25.9] 25.4 [24.8–25.9] 25.6 [25.0–26.3] 0.5492
LVEF(†) 22.4 [21.8–22.9] 22.7 [21.9–23.4] 22.1 [21.4–22.8] 0.2529
CTR(†) 59.1 [58.3–59.4] 57.5 [56.4–58.6] 60.4 [59.3–61.4] 0.0003
Non-sinus rhythm (%) 25.6 14.3 35.5 , 0.0001
Heart rate (beats/min) 86.5 [85.0–88.0] 83.7 [81.7–85.7] 88.9 [86.7–91.1] 0.0007
Serum sodium (mmol/L) 138.3 [137.8–138.6] 137.8 [137.2–138.4] 138.6 [138.1–139.2] 0.0450
Serum creatinine (mmol/L) 129.8 [123.6–136.0] 137.1 [127.7–146.7] 123.4 [115.4–131.4] 0.0274
Serum potassium (mmol/L) 4.2 [4.1–4.3] 4.2 [4.1–4.3] 4.2 [4.1–4.3] 0.2044
*Comparison of coronary heart disease (CHD) vs. non-CHD (Non-CHD); †Left ventricular ejection fraction (LVEF) and cardiothoracic ratio (CTR) data were available in 459
(216 CHD, 243 Non-CHD) and 309 (139 CHD, 170 Non-CHD) patients, respectively.
Table 2. Drug Therapy at Discharge From Hospital Following
Enrollment (n 5 417)
N %
Total diuretics 404 96.9
Potassium-sparing diuretics 47 11.3
Potassium supplements 275 66.0
ACE inhibitors 312 74.8
Digitalis 207 49.6
Amiodarone 140 33.5
Class I antiarrhythmic drugs 13 3.1
Nitrates 170 40.7
Other vasodilators 62 14.8
Antiplatelet agents 133 31.9
Oral anticoagulants 118 28.3
Beta-blockers 22 5.3
Calcium-channel blockers 53 12.7
*Of 499 patients, 69 died during the hospitalization following enrollment and 13 had
incomplete treatment records.
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aged between 20 and 80 years, 289 not admitted within
study period, 552 had a LVEF .30% and/or a CTR ,60%,
106 no evidence of class III or IV dyspnea and edema or
hypotension and 11 incomplete data). Thus, 499 patients
had all the inclusion criteria and were enrolled into the
study. Among these, LVEF data were available for 466
patients (93.4%); for the other 33 patients (6.6%), the only
criterion of left ventricular dysfunction was a CTR greater
than 60%.
Incidence and patient characteristics. Of the 499 patients
enrolled into the study, 358 had not been hospitalized for
CHF during the preceding 18 months and were considered
to be incident cases of advanced CHF. Using an estimate of
1,592,263 people in the Lorraine region aged between 20
and 80 years, this corresponds to an incidence rate for
advanced CHF of 225 per million (95% CI 5 202–249).
Incidence rate varied from 6 per million (CI 5 0–32 per
million) in women aged less than 30 years to 1,480 per
million (1,164–1,855 per million) in men aged 70–80 years
(Fig. 1).
Patient characteristics are summarized in Table 1. The
socioeconomic characteristics of the patients from the entire
cohort were comparable to those of the age- and gender-
adjusted population of Lorraine. Overall, 9.2% were profes-
sionally active, 63.9% were retired, 50.7% were civil servants
and blue-collar workers, 22.4% had a nonmanual occupa-
tion and 26.1% had no hobbies; 85.8% received only
primary level education.
Attributable causes of CHF included CHD (n 5 231;
46.3%) (history of MI in 202 patients [87.4%]) and non-
CHD causes (n 5 268; 53.6%) (congenital heart disease
[n 5 3], valvular heart disease [n 5 4], dilated cardiomy-
opathy [n 5 214], unknown causes [n 5 47]).
Of the dilated cardiomyopathy group, 157 (31.5% of the
total cohort) had at least one concomitant predisposing or
contributing risk factor: alcohol abuse (37.6%), arterial
hypertension (61.8%) and/or other rare conditions (20.4%).
Other rare conditions included: thyroid disease (n 5 14;
9.0%), immune system dysfunction, history of cancer che-
motherapy, postpartum heart disease, thalassemia, toxic
syndrome, sick sinus syndrome, myocarditis and obstructive
cardiomyopathy. No contributing risk factors were seen in
the 57 patients (11.4% of the total cohort) who were
considered to have idiopathic cardiomyopathy.
Eighty-seven patients had undergone a coronary angio-
gram. Within the cardiomyopathy subgroup, these patients
differed from those who had not undergone a coronary
angiogram only in the fact that they were younger (58 6 10
years vs. 66 6 10 years, respectively; p , 0.0001).
The non-CHD group differed significantly from the
CHD group in terms of older age, higher ratio of males to
females, more frequent cigarette use, less frequent alcohol
abuse, greater history of diabetes and hyperlipidemia, and
higher rate of nonsinus rhythm (Table 1). Table 2 summa-
rizes the drugs patients were using at discharge from the
hospitalization immediately preceding enrollment into the
study. Only three percent of the patients were not receiving
diuretic therapy at discharge. This therapy had been dis-
continued in four patients after heart transplantation, and
eight others had been temporarily withdrawn from diuretics
Figure 1. Incidence of advanced congestive heart failure according to age and gender.
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for various reasons (acute renal failure, hypotension, dehy-
dration, initiation of ACE inhibitor therapy). Drug pre-
scription patterns during follow-up did not change signifi-
cantly, except for the prescription of statins, which increased
steadily from use in 3.6% of patients on discharge to use in
24% of patients surviving at 18 months.
Patient outcomes. Survival status was obtained for all
patients as of 31 December 1995. Average follow-up was 18
months (range 12–24 months). One-year mortality was
35.4% for the whole cohort (Fig. 2) and was not affected by
gender when adjusted for age. Mortality during the initial
enrollment was 13.8%. The relative risk of death conferred
by advanced CHF, adjusting for age and gender was 12.7
(95% CI 10.9–14.4).
During the follow-up period, 20 patients received a heart
transplant, two of whom had previously used the cardiac
assist Novacor™ system. One other patient died while on a
cardiac assist device. Survival analysis was censored for heart
transplantation. Of the transplanted patients, 15 were still
alive at the end of follow up.
The one-year rate for all-cause hospitalization was 2.01
(95% CI 2.00–2.03). It was 2.18 (95% CI 2.16–2.21) in
CHD and 1.99 (95% CI 1.96–2.02) in dilated cardiomy-
opathy subgroup. The cumulative length of hospital stay
was 26.4 days per year (95% CI 26.1–26.7), corresponding
to an average yearly rate of hospitalization of 2.05 (95% CI
2.04–2.07). It varied from 28.3 (95% CI 27.9–28.6) to 24.8
(95% CI 24.3–25.3) in the CHD and dilated cardiomyop-
athy subgroups respectively (p , 0.0001). The hospital
readmission-free survival curve is depicted in Figure 3.
Within the follow-up period, the cause of hospitalization
was known for 684 of the 1,074 hospitalizations for the
whole cohort. Hospitalization was related to worsening of
CHF in 50.3% of patients, to other cardiac causes in 29.7%
and to noncardiac causes in 20.0% of patients. Survival, but
not hospital readmission-free survival, varied significantly
according to the attributable cause of CHF, and was greater
in the dilated cardiomyopathy subgroup (Fig. 2). In this
subgroup of patients, age-adjusted one-year survival did not
differ according to whether the patient had or had not
undergone normal coronary angiography (77% vs. 64%; not
significant).
DISCUSSION
To date, the EPICAL study is the only descriptive, obser-
vational, community-based cohort study with a prospective
one-year survival period that provides epidemiological de-
scriptors of advanced CHF in a Western country within the
ACE inhibitor and heart transplantation era. Among the
epidemiological studies of CHF published after 1989 (8–
10,14–21), only three specifically addressed patients with
advanced CHF (8–10,14). All three were, however, re-
stricted to single centers where patients were referred for
emergency admission (10,14) or for transplant programs
(8,9).
Diagnostic criteria and definition of advanced CHF.
The lack of agreement of a definition of CHF, as well as the
lack of gold-standard diagnostic criteria, may result in a
considerable heterogeneity in the diagnosis of CHF in
clinical trials and in epidemiological studies (7). The defi-
nition of CHF should combine clinical features with an
Figure 2. Survival of patients with advanced congestive heart failure (including index hospitalization mortality) (Censorship is represented
by vertical bars).
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objective measure of cardiac performance (22). It is to be
emphasized that the aim of the present study was to select
only patients with advanced heart failure. Thus, a combi-
nation of clinical symptoms (class III and IV dyspnea) and
signs of fluid retention and of severe left ventricular dys-
function were used to diagnose CHF. An LVEF of less than
30% was arbitrarily chosen as a cut-off point for severe left
ventricular dysfunction, a percentage that has been used
previously in published studies of advanced CHF
(8,9,23,24).
The definition of advanced CHF used in the EPICAL
study excluded patients with preserved or normal systolic
function, even if severe symptoms of fluid retention were
present. In advanced CHF, however, diastolic failure with
no evidence of systolic failure is usually rare (25,26).
Incidence of advanced CHF. The incidence of CHF
found in the EPICAL study is consistent with all previously
published data, and the results show that the incidence of
advanced CHF increases dramatically with increasing age.
In EPICAL, patient entry was restricted to those less than
80 years of age because of the high numbers of institution-
alized men and women aged over 80 years who would
escape the case finding procedures used. Consequently, the
results of EPICAL cannot be extrapolated to all patients
with advanced CHF. The gender ratio reported in EPICAL
was comparable to that reported in the Study Of Left
Ventricular Dysfunction (SOLVD), which included asymp-
tomatic patients and those with less severe symptoms than
the patients included in EPICAL (27).
Etiology. When all possible etiological or risk factors, such
as hypertension and alcohol abuse, were excluded, the rate
of “idiopathic” dilated cardiomyopathy in EPICAL was
11%. A similar approach was used in the SOLVD studies,
where the resulting rate of dilated cardiomyopathy was 18%
(28). In the Framingham Heart Study (3), 11.2% of the men
and 16.8% of the women had CHF that was not attributable
to hypertension, CHD or rheumatic fever. Conversely, as in
other series (23,29), a large majority of patients with CHD
in EPICAL had a history of MI, because this was the most
readily available hard evidence of CHD. Thus, patients
diagnosed as having a nonischemic heart disease may
actually have undiagnosed ischemic heart disease, but,
because they did not experience an MI or severe angina or
undergo a coronary angiogram, this was not identified. In
postmortem studies up to 34 to 50% of patients diagnosed
with nonischemic dilated cardiomyopathy have been shown
to have significant coronary artery narrowing (30,31).
In EPICAL, 44% of the CHD subgroup had hyperten-
sion or a history of hypertension, a similar percentage to
those patients whose CHF was attributable to CHD. The
high incidence of a history of hypertension in the EPICAL
cohort is consistent with that reported for CHF in the
Framingham study (32), and SOLVD (28) and the Flolan
International Randomized Survival Trial (FIRST) (23).
Hypertension was the sole cause of CHF in 13.8% of the
EPICAL patients, a relatively high percentage when compared
to that reported in white patients in SOLVD (7%) (27).
Alcoholic cardiomyopathy is a well-known entity and
alcohol abuse is a strong risk factor for idiopathic dilated
Figure 3. Hospital readmission-free survival in patients with advanced congestive heart failure (censorship is represented by vertical bars).
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cardiomyopathy (33–35). A number of studies (36,37) have
shown that disease progression is different in alcoholic
cardiomyopathy compared with idiopathic dilated cardio-
myopathy. In EPICAL, 19% of patients presented with
alcohol abuse, and the level of alcohol abuse appeared higher
in the non-CHD subgroup than in the CHD subgroup
(26% vs. 11%, respectively).
Outcome, survival and hospital re-admission. Although
multiple clinical trials with pharmacological agents have
been conducted that describe survival in CHF patients,
patients enrolled in these trials do not depict an accurate
picture of CHF in usual care. Very few observational studies
have reported survival data in CHF patients who have
received optimal, up-to-date, management, including ACE
inhibition. Single-center series tend to reflect the patient
population of the specialists’ referral hospital(s), and thus
often include younger patients, who are more usually eligi-
ble for cardiac transplantation or for aggressive therapy
(8,9). Data on the prognosis of advanced CHF from clinical
trials may be also biased as a result of highly selective entry
criteria (23,24). Published information concerning the rate
of hospital admission of patients with advanced CHF is
even scarcer. The EPICAL study is the first to report
detailed information on readmission-free survival, hospital
readmission rates, primary causes of hospitalization and
length of hospital stay. This information is required (par-
ticularly for the calculation of sample sizes) when designing
an outcome trial in patients with advanced CHF.
Readmission-free survival is extremely poor in advanced
CHF: less than 20% of EPICAL patients were not read-
mitted to hospital and survived at one-year follow-up.
The effect of aging on the prognosis of CHF remains a
controversial issue, and it has not been reported to be an
independent predictor of death in recent studies with severe
CHF (8–10,38,39). In the EPICAL cohort, mortality was
independently affected by age: patients aged 70 to 80 years
had a 50% higher risk of death than those aged less than 70
years. This may explain the higher mortality among women
since, when adjusted for age, survival was not related to
gender.
There is also conflicting evidence as to whether CHF
patients with underlying CHD have a better or worse
prognosis than those with CHF due to other causes.
Patients with ischemic CHF have been reported to have a
worse (27,29,40,41), comparable (42) or better (21) prog-
nosis than patients with CHF of nonischemic etiology.
These discrepancies may be partly explained by selection
biases in hospital series of patients and partly by possible
etiological misclassification. In the present study, patients
with ischemic CHF carried a significantly increased (30%)
risk of death compared to patients whose CHF was due to
nonischemic causes.
Study limitations. The methodology of patient enrollment
used in EPICAL allowed the identification of incident cases
of advanced CHF. According to the definition of CHF
used, which required at least one hospital admission for
signs and symptoms of severe CHF, incident cases were
comprehensively recorded. The organization of the French
healthcare system permits easy and immediate access to the
hospital. Moreover, patient registration was not only pas-
sive, but also active and randomly audited via the review of
medical records by trained clinical research nurses. Never-
theless, despite considerable efforts to ascertain complete
and comprehensive patient notification, we may have missed
few cases, especially among patients admitted with other
initial diagnoses. Thus, our incidence figures may be slightly
underestimated. Moreover, because of the relatively short
follow-up period, it was not possible to provide a relevant
estimation of the prevalence of advanced CHF.
In extrapolating these data to other Western countries, it
should be borne in mind that the incidence of morbidity and
mortality from cardiovascular disease, and especially from
CHD, is significantly lower in France when compared to
other European countries and to the U.S.A. (although the
Lorraine region has one of the highest incidences of
cardiovascular morbidity and mortality in France) (43)
(standardized mortality ratio: 1.3).
Conclusions. Despite the above limitations, the EPICAL
study is the only observational epidemiological study avail-
able to date that provides estimates of the incidence of
advanced CHF, together with information regarding out-
come and use of medication, for a large Western community
population in the post-ACE inhibitor and heart transplan-
tation era. The findings of this study may aid estimating and
decision making concerning the utilization of healthcare
resources, especially costly interventional surgical proce-
dures. Further analyses of our database would estimate the
use of healthcare resources and the utilization of medication
and may help in the design of managed-care strategies.
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Hoˆpitaux de Brabois; Hoˆpitaux (Community Hospitals) de: Bar le Duc, Boulay, Briey,
Creutzwald, Epinal, Forbach, Lune´ville, Metz (Bon Secours, Saint Andre, Sainte
Blandine, Hoˆpital d’instruction Des Arme´es Legouest), Mont Saint Martin, Neufchateau,
Pont-a-Mousson, Rambervillers, Remiremont, Saint Avold, Saint Die´, Saint-Dizier,
Sarrebourg, Sarreguemines, Saverne, Thionville, Verdun, Vittel; Cliniques (private
hospitals): C. Bernard a` Metz, Essey, Peupliers a` Villerupt, Notre Dame a` Saint-Die´;
Centres de Re´adaptation d’Abreschviller et de Niderviller.
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